Abstract. Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a Kunitz-type serine protease inhibitor that has a broad inhibitory spectrum against serine proteases. This is the first study to investigate the role of HAI-1 and its clinical importance in cervical cancer. We attempted to investigate the inhibitory effects of HAI-1 using cervical carcinoma cell lines SiHa with integrated human papillomavirus (HPV) 16 and HeLa with integrated HPV 18. HAI-1 expression in cervical cancer (n=91) were assessed by immunohistochemistry. HAI-1 was found to be a potential inhibitory effects mediated by reduction of hepsin, matriptase and prostasin expression. This led to apoptosis through a reduction in the levels of Bcl-2, Bcl-xL, MUPP-1 and MAGI-3 in cervical cancer cell lines. There were significant correlations between HAI-1 expression and stage (p=0.013), tumor size (p=0.002), stromal invasion (p<0.001), vaginal invasion (p=0.031), parametrial invasion (p=0.012), lymph-node metastasis (p=0.019), and LVS involvement (p=0.002). The disease-free and overall survival rates of patients exhibiting high HAI-1 expression were significantly higher than those of patients exhibiting low HAI-1 expression (p=0.022 and p=0.011, respectively). The present study proposes that these findings may be considered HAI-1 as a therapeutic target for treatment and identify as a favorable prognostic marker for cancer patients of cervical cancer.
Introduction
Cervical cancer is the most important manifestation of human papillomavirus (HPV) infection and is one of the leading causes of cancer mortality in women worldwide. The causal roles of some high-risk HPV types in cervical carcinogenesis has now been clearly established by studies that take into account the many molecular, epidemiological, virological, cytological and histological complexities of the natural history of the disease (1) .
Cell surface proteolysis is suggested to play a major role in cancer progression and metastasis through the processing of macromolecules important for regulating the extracellular environment. The cell surface localization, high activity, and exquisite specificity of the type II transmembrane serine protease suggest a role in outside-in signaling and interaction with the microenvironment. Members of the type II transmembrane serine protease family, such as hepsin and matriptase are highly expressed in many cancers, including those of the cervix, prostate, breast and ovarian cancer (2) (3) (4) (5) (6) . Matriptase and hepsin have been proposed to initiate signaling and proteolytic cascades through its ability to activate prourokinase plasminogen activator (uPA) (7) (8) (9) . Matriptase is known to interact with the glycosylphosphatidylinositolanchored membrane serine protease of prostasin (10) . Matriptase, hepsin and prostasin are potential candidates for the cellular activities of pro-hepatocyte growth factor (pro-HGF) in cancer tissues (11) (12) (13) . Importantly, the activities of these proteinases are closely controlled in the pericellular microenvironment by HGF activator (HGFA) inhibitor (HAI). HAI is a type I transmembrane protein with two Kunitz-type serine proteinase domains (KDs) and in its extracellular portion. Two types of HAI have been identified so far, HAI-1 and HAI-2, both of which show cell surface expression on epithelial cells. Therefore, overall structures of the characteristic domains are very similar between HAI-1 and HAI-2. In addition, between KDs, HAI-1 has the ligand binding region of low-density lipoprotein (LDL) receptor. HAI-1 is synthesized as a transmembrane protein on the cell surface and appears to be subsequently shed, but membraneform HAI-2 cannot. The membrane-bound HAI-1 is able to form a complex with active HGFA and may function to temporarily sequester HGFA to the cell surface and serve as a reservoir for HGFA (14) . The shed form of HAI-1 is active in inhibiting HGFA, matriptase, hepsin and prostasin, all of which are pro-HGF activators (11, 15, 16) . The functional relevance of HAI-1 inhibition of matriptase was confirmed in a transgenic mouse model in which matriptase-induced skin tumorigenesis was completely prevented by the overexpression of HAI-1 in the same tissue (17) . To date, several studies on HAI-1 expression in tumor tissues have been published. In prostate, breast and gastric cancer it has been reported that the reduced expression of HAI-1 is possibly involved in the cancer progression (18) (19) (20) . However, it is not clear how HAI-1 is involved that the role of HAI-1 in cervical cancer.
In order to shed light on the role of HAI-1 in cervical cancer, we examined whether HAI-1 protein expression correlates with clinicopathological characteristics in patients suffering from cervical cancer. The main aim of this study was to determine whether HAI-1 protein could be considered as a therapeutic target for treatment and used as a favorable prognosis marker for patients of cervical cancer.
Materials and methods
Cell culture, media and generation of transfectants. HeLa (ATCC no. CCL-2), Caski [Japanese Collection of Research Bioresources (JCRB) no. IFO50007], SiHa (ATCC no. HTB-35) and Yumoto cancer cell lines were derived from human cervical carcinomas. Yumoto cells were kindly provided by Dr A. Mitsuhashi (Chiba University, Chiba, Japan), as described previously (21) . HPV 16 type Caski and SiHa cell lines, 18 type HeLa cell lines and non-HPV type Yumoto were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS) at 37˚C in an atmosphere with 5% CO 2 in air. A cDNA encoding the whole coding region of HAI-1 was constructed by polymerase chain reaction using full-length HAI-1 cDNA as a template. Primers used were, 5'-TTGGAATTCGCGATGGCCCCTGCGAGGAC-3' and 5'-TTAGTCGACTCAGAGGGGCCGGGTGGTGT-3' for HAI-1. The polymerase chain reaction products were subcloned into the EcoRI/SalI site of an expression plasmid pCIneo (Promega, Madison, WI). A HAI-1 cDNA expression vector was transfected into all cervical cancer cell lines using TransFast transfection reagent (Promega). Mock transfected cells served as a control.
Western blotting analysis. Cell lysates were collected and estimated using a Protein Assay system (Bio-Rad, Hercules, CA) according to the manufacturer's protocols. Proteins from each cell line were subjected to SDS-PAGE and were transferred onto a nitrocellulose membrane. The polyclonal and monoclonal antibodies used for immunoblotting were as follows: HAI-1, matriptase, prostasin, Bcl-2, Bcl-xL, MUGG-1 and MAGI-3 (Santa Cruz Biotechnology, Santa Cruz, CA), hepsin (Cayman Chemical, Ann Arbor, MI) and ‚-actin (Sigma Chemical, St. Louis, MO). The working dilution of all primary antibodies was 1:1000. After incubation of membranes with the appropriate secondary antibodies, antigen-antibody complexes were detected using an enhanced chemiluminesence kit (Amersham Biosciences, Piscataway, NJ).
Matrigel invasion assay. To investigate differences in the invasive abilities of cells expressing HAI-1, we used BioCoat Matrigel Invasion Chambers (BD Bioscience, Bedford, MA). SiHa and HeLa cervical cancer cells with or without transient transfection of the HAI-1 vector were incubated in situ with 10 μg/ml of DiI (Invitrogen) in DMEM containing 10% FBS for 1 h. The labeled cells (5x10 4 ) of each genotype were then added to the chambers inserts, and 0.75 ml of medium was added to the bottom of each well. After 48 h of incubation, the membranes were removed from the insert and mounted on slides, and the numbers of invading cells were counted under the microscope. The matrigel assays were performed in triplicate.
MTS assay. The effects of HAI-1 on cell proliferation were evaluated using the MTS assay (Promega). Cells were seeded into 96-well plates and cultured until the cell density reached 5x10 4 cells/well. The cells were then transiently transfected with the HAI-1 vector for 48 h. After incubation with MTS for 1 h, the absorbances were measured at a wavelength of 490 nm using an ELISA plate reader (Bio-Rad Systems).
Cell cycle and FITC-conjugated Annexin V analysis.The cells subjected to transient transfection of the HAI-1 vector were trypsinized, washed twice with phosphate-buffered saline, incubated with trypsin for 10 min at room temperature, incubated with trypsin inhibitor and RNase buffer for 10 min at room temperature, and stained with 200 μl propidium iodide staining solution for 10 min in the dark, at room temperature (Becton-Dickinson, San Jose, CA). Finally, the cell cycles were analyzed with the FACS cytometer. In addition, apoptosis was measured by staining with FITCconjugated Annexin V using a MEBCYTO apoptosis kit (MBL, Nagoya, Japan) according to the manufacturer's recommendations and flow cytometry analysis (Calibur TM , Becton-Dickinson).
Cell growth in a monolayer and in soft agar. To obtain a monolayer of cell growth, cells were plated at a density of 3x10 4 cells/well in 6-well plates containing DMEM with 10% FBS. The cell numbers were counted in triplicate after 2, 4, 6, 8 and 10 days using a hemocytometer to assess cell proliferation. For the soft agar determination of cell growth, a cell suspension (1x10 4 cells/well) in 1 ml 0.2% Noble Agar DMEM with 10% FBS was overlaid onto a 35 mm dish containing a 0.5% agar base. Colonies >0.2 mm in diameter were counted 21 days after culture. Soft agar assays were performed in triplicate.
Patients. The patient population consisted of 91 patients presenting with the International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIB cervical cancers. Each of these patients underwent radical hysterectomy and pelvic lymphadnectomy at the Department of Obstetrics and Gynecology of Okayama University Hospital. Patients with neoadjuvant chemotherapy were excluded from this study.
Tumor specimens were obtained at the time of surgery, immediately fixed in 10% neutral-buffered formation and then embedded in paraffin. The histological cell types were conducted according to the WHO classification as follows: 54 were classified as squamous cell carcinomas, 27 as adenocarcinomas and 10 as adenosquamous carcinomas. Clinical staging was assessed based on the FIGO staging system as follows: 45 were allocated to stage IB, 5 to stage IIA and 41 to stage IIB. The median age at the time of surgery was 45 years (range 27-66 years). Patients with lymph node metastasis, parametrial involvement, deep stromal invasion or marked lymph-vascular space involvement were treated with an adjuvant external whole pelvic irradiation, combination chemotherapy or chemoradiation. The disease-free survival (DFS) and overall survival (OS) rates were defined as the interval from the initial surgery to clinically or radiologically proven recurrence and death, respectively. The end date of the follow-up study for conducting the analysis was 30th September 2007, and median duration of the follow-up was 79 months (range 4-146).
Immunohistochemical analysis and staining evalution.
Formalin-fixed paraffin-embedded sections at 4 μm thick were deparaffinized with xylene and rehydrated in ethanol. Endogenous peroxidase activity was quenched by treatment with methanol containing 0.3% hydrogen peroxidase for 15 min. Then, the sections were incubated with a primary antibody for HAI-1 at room temperature, followed by staining with a streptavidin-biotin-peroxidase kit (Nichirei, Tokyo, Japan). The sections were counterstained with hematoxylin. The levels of HAI-1 staining in the tumors were classified into three groups by scoring the percentages of positively stained cell: 2, strong staining, >50% of cells; 1, moderate staining, 10-50% of cells; and weak staining, <10% of cells. Two independent examiners with no prior knowledge of the patient clinical data conducted the microscopic evaluations. Controversial cases were evaluated using a conference microscope.
Statistical analysis. Statistical analyses were performed using the Mann-Whitney U test for comparison with the control and one-factor ANOVA followed by Fisher's protected least significance difference test for all-pair wise comparisons. Analyses were performed with the software package Stat View version 5.0 (Abacus Concepts, Berkeley, CA). Differences were considered significant at p<0.05. MTS assay by HAI-1. We used MTS assays to examine cell proliferation into Caski, SiHa, Hela and Yumoto cervical cancer cell lines caused by HAI-1. The transient transfection of the HAI-1 vector into these fourth cervical cancer cell line caused reduced cell growth by MTS assay. And, the inhibitory effect was most prominent in HeLa cervical cancer cell lines (Fig. 1B) . (Fig. 1C) .
Matrigel invasion assay by HAI-1. We assessed the motility and invasiveness of SiHa and HeLa cells overexpressing HAI-1 by using a BioCoat Matrigel invasion chamber. Cells were plated on the upper surface of the membrane, and transient transfection of HAI-1 after 48 h. Next, the cells invading to the bottom side of the membrane were stained and counted. The percentage of cells reaching the bottom of the filter were decreased to 58.32 and 38.81% at 48 h after transient transfection of the HAI-1 vector into SiHa and HeLa cells, respectively (Fig. 1D) .
Cell cycle assay by HAI-1. Cells usually respond to genotoxic stress by activating cell cycle checkpoints and by blocking further progression into the cell cycle, allowing the cells to lines. We found a significant inhibitory effect of HAI-1 on cell growth transient transfection of the HAI-1 vector into both the SiHa and HeLa cell compared to control cells (p<0.05) (Fig. 3B) . Furthermore, the colony forming assay showed that the transient transfection of the HAI-1 vector into SiHa and HeLa cell resulted in a significantly reduced number of colonies compared with control cells (p<0.01) (Fig. 3C) . Immunoassays by HAI-1. HAI-1 expression in human cervical cancer specimens was examined by immunoassays. The representative immunoassaying patterns of HAI-1 are shown in Fig. 4 . Weak HAI-1 staining was observed in 16 cases (17.6%), moderate HAI-1 staining in 37 cases (40.6%) and strong HAI-1 staining in 38 cases (41.8%). Table I shows the distribution of cases scored as positive for each of the biological parameters examined, according to the clinicopathological characteristics in the overall population. As expected, the results showed a statistically significant association with clinicopathological parameters such as stage (p=0.013), tumor size (p=0.002), stromal invasion (p<0.001), vaginal invasion (p=0.031), parametrial invasion (p=0.012), lymph-node metastasis (p=0.019) and LVS involvement (p=0.002), but age, histological type and ovarian metastasis were not statistically significant (MannWhitney U test, p<0.05).
Univariate survival analysis.
The results of the univariate survival analyses of other variables are shown in Table II . Overall, HAI-1 was most significantly exhibited on DFS and OS analysis of the prognostic factor for cervical cancer using the log-rank test. The DFS and OS curves of 91 cervical cancer patients according to their HAI-1 expression status are Table I . Association between HAI-1 and clinicopathological factors in cervical cancer. 
Mann-Whitney U test; FIGO, International Federation of Gynecology; LVS, lymph-vascular space. Fig. 5A and B, respectively. The DFS and OS rates of patients exhibiting high HAI-1 expression (score 2) were significantly higher than those of patients exhibiting low HAI-1 expression (score 0-1) (p=0.022 and p=0.011, respectively) (Mann-Whitney U test, p<0.05).
Discussion
Cervical cancer is the most important manifestation of genital HPV infection. HPV viruses encode the E6 and E7 oncogenes, which are essential for malignant transformation as well as maintenance of the malignant phenotype of cervical cancer. The E6 protein forms a tertiary complex with ubiquitinmediated degradation, including p53 and PDZ domaincontaining protein (MUGG-1 and MAGI-3) (22) (23) (24) . The E7 protein binds directly to inactivate a number of cell cycle regulatory proteins, including family of retinoblastoma protein (25) . Several studies have demonstrated that these oncogenes make ideal targets for gene-specific therapy for cervical cancer. However, to date, their effectiveness has Table II . DFS and OS analysis of prognostic factor using the log-rank test in cervical cancer. 
Mann-Whitney U-test; FIGO, International Federation of Gynecology and Obstetrics; LVS, lymph-vascular space.
It is now widely accepted that new approaches for the treatment of cervical cancer are pivotal in further improving the prognosis of this disease. This is the first study to investigate the role of HAI-1 and evaluate its clinical importance in cervical cancer. HAI-1 is a Kunitz-type serine protease inhibitor that has a broad inhibitory spectrum against serine proteases. HAI-1 is an endogenous inhibitor of hepsin, matriptase and prostasin. Hepsin, matriptase and prostatsin are a serine proteinase domain, and show enhanced expression in a variety of tumor tissues (26) . Hepsin and matriptase has been proposed to initiate signaling and proteolytic cascades through its ability to activate pro-uPA, and matriptase is known to interact with prostasin (7) (8) (9) (10) . In this study, hepsin, matriptase and prostasin were significantly inhibited by HAI-1 in cervical cancer cell lines (Fig. 1C) .
Parr and colleagues have reported that HAI-1 expression significantly enhanced the migratory, proliferative and invasive nature of breast cancer cell lines (27) . However, the impact on apoptosis from HAI-1 overexpression remains unclear. In this report, we observed significant inhibition which resulted in apoptosis by HAI-1, as shown in Fig. 2A and B. Furthermore, HAI-1 was likely to regulate the early apoptosis process. To trace the steps in the apoptotic cascade, we evaluated the activation of pro-and anti-apoptotic protein (28) (29) (30) . HAI-1 was able to down-regulate both Bcl-2 and Bcl-xL, thereby inducing apoptosis (Fig. 3A) .
The E6 and E7 proteins of HPV immortalize, at least in part, the inactivation of the tumor suppressor proteins p53 and PDZ domain-containing protein and RB protein (22) (23) (24) (25) . These tumor suppressor proteins also regulate the expression of pro-and anti-angiogenic factors by cells. For this reason, experiments were conducted to determine the role of HAI-1 on p53, PDZ domain-containing protein (hDlg, MUGG-1 and MAGI-3) and RB proteins. The expression of PDZ domaincontaining protein (MUGG-1 and MAGI-3) was downregulated in the cells transiently transfected with HAI-1 (Fig. 3A) . However, HAI-1 was not correlated with the levels of the p53, hDlg and RB protein (data not shown). Overall, HAI-1 shows potential inhibitory effects mediated by reduction of hepsin, matriptase and prostasin, which leads to apoptosis through a reduction in the level of Bcl-2, Bcl-xL, MUPP-1 and MAGI-3.
In clinical case, prostate, breast and gastric cancer has been reported that the reduced expression of HAI-1 is possibly involved in the progression of these cancers (18) (19) (20) . The current study, the immunohistochemistry of cervical cancers from chemo-naive patients showed decreased HAI-1 protein expression that increased with stage of cancer, tumor size, stromal invasion, vaginal invasion, parametrial invasion, lymph-node metastasis and LVS involvement. Interestingly, a low HAI-1 immunostaining pattern was significantly associated with poor prognosis in cervical cancer (Fig. 5A  and B) . These findings all indicate that HAI-1 protein could be an important tool for identifying patients with a favorable prognostic marker of cervical cancer.
In summary, these studies have revealed a critical role for HAI-1 in the disruption of the basement membrane of cervical cancer. These findings identify HAI-1 as a favorable prognostic marker for patients and could be considered as a therapeutic target for certain approaches to the treatment of cervical cancer.
